49. Clinical benefit table: Suplasyn. Continuous outcome measures.

Study	Time	Treatment	Outcome (scale)	N of Pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
Petrella 2002	1‐4 wk	E: Suplasyn+lactose	WOMAC pain (0‐10 cm)	30	3.32	2.42	‐0.47 (I)	‐13% (I)
		C: Saline+lactose		30	3.62	3.19
		C: Saline+NSAID		30	4.22	2.86	0.46 (W)	11% (W)
		C: Suplasyn+NSAID		30	3.65	2.59	0.16 (W)	4% (W)
Petrella 2002	1‐4 wk	E: Suplasyn+lactose	WOMAC function (0‐10 cm)	30	4.10	2.45	‐0.66 (I)	‐14% (I)
		C: Saline+lactose		30	4.72	3.73
		C: Saline+NSAID		30	4.32	2.76	‐0.09 (I)	‐2% (I)
		C: Suplasyn+NSAID		30	3.90	2.73	‐0.48 (I)	‐12% (I)
Petrella 2002	1‐4 wk	E: Suplasyn+lactose	WOMAC stiffness (0‐10 cm)	30	4.60	2.95	‐1.53 (I)	‐30% (I)
		C: Saline+lactose		30	5.12	5.00
		C: Saline+NSAID		30	5.14	2.80	0.69 (W)	13% (W)
		C: Suplasyn+NSAID		30	4.82	2.71	0.46 (W)	10% (W)
Petrella 2002	1‐4 wk	E: Suplasyn+lactose	Rest pain (0‐10 cm)	30	3.29	2.60	0.84 (W)	25% (W)
		C: Saline+lactose		30	3.30	1.77
		C: Saline + NSAID		30	3.34	1.58	1.07 (W)	32% (W)
		C: Suplasyn+NSAID		30	3.60	1.56	1.35 (W)	38% (W)
Petrella 2002	1‐4 wk	E: Suplasyn+lactose	Self‐paced walk pain (0‐10 cm)	30	3.94	2.89	‐1.08 (I)	‐31% (I)
		C: Saline+lactose		30	3.53	3.56
		C: Saline+NSAID		30	3.78	1.81	0.92 (W)	24% (W)
		C: Suplasyn+NSAID		30	3.84	2.05	0.74 (W)	19% (W)
Petrella 2002	1‐4 wk	E: Suplasyn+lactose	Walk time (sec)	30	77.23	74.21	‐3.53 (I)	‐5% (I)
		C: Saline+lactose		30	70.56	71.07
		C: Saline+NSAID		30	77.64	75.70	‐1.08 (I)	‐1% (I)
		C: Suplasyn+NSAID		30	78.81	72.22	3.57 (W)	5% (W)